2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2211 Outcomes of daratumumab monotherapy after lenalidomide discontinuation in newly diagnosed and in relapse/refractory multiple myeloma patients - a retrospective cohort trial

Tamir Shragai, MD, Noa Lavi, MD2, Ori Grossberger, MD3, Eyal Label4, Iuliana Vaxman, MD, BA5, Hila Magen6, Miri Zektser, MD7, Chezi Ganzel III, MD8, Svetlana Trestman, MD9, Natan Melamed10, Danielle Kaplan11, Ido Cohen12, Hadas Bar13, Irit Avivi Mazza, MD14, Yael C. Cohen, MD15
2 Rambam Health Care Campus, Haifa, Israel, Technion-Israel Institute of Technology, Haifa, Israel
3 Tel-Aviv Sourasky University Hospital, Tel-aviv, Israel
4 Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, Hadassah Medical Center, Jerusalem, Israel
5 Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel, Tel-Aviv university, Tel-aviv, Israel
6 Department of Haematology, Chaim Sheba Medical Center, Ramat-Gan, Israel, Tel-Aviv university, Tel-aviv, Israel
7 Department of Haematology, Soroka University Medical Center, Beer-Sheva, Israel, Faculty of medicine, Ben Gurion University, Be'er Sheva, Israel
8 Department of Haematology, Shaare Zedek Medical Center, Jerusalem, Israel, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
9 Tel-Aviv Sourasky University Hospital, Tel-aviv, Israel
10 Tel-Aviv Sourasky University Hospital, Tel-aviv, Israel
11 Department of Haematology, Chaim Sheba Medical Center, Ramat-Gan, Israel
12 Hadassah Medical Center, Jerusalem, Israel
13 Rambam Health Care Campus, Haifa, Israel
14 Tel-Aviv Sourasky University Hospital, Tel-aviv, Israel, Tel-Aviv university, Tel-aviv, Israel
15 Tel-Aviv Sourasky University Hospital, Tel-aviv, Israel, Tel-Aviv university, Tel-aviv, Israel

Background: Most induction and early-relapse regimens for multiple myeloma (MM) include a daratumumab (DARA)/lenalidomide (LEN) backbone (DR). In most clinical trials investigating these combinations, LEN is continued until progression. In practice, LEN is not infrequently omitted at some point, either due to adverse events (AEs) or concern of long-term toxicities, mainly MDS and solid secondary malignancies (SSM).

Methods: A retrospective cohort study, including MM patients (pts) who initiated DR-based combination therapy between 1-JAN-15 and 31-DEC-24 in 7 hospitals, discontinued LEN at some time-point and remained on DARA monotherapy. Two different cohorts were defined: newly diagnosed MM (NDMM) pts receiving DR combination as 1st line, and pts on 2nd or subsequent line. The primary endpoint was event-free survival (EFS) from time of LEN discontinuation (d/c). Event was defined as progression (PD), death or any change in therapy (including radiation). High-risk (HR) cytogenetics were defined as t 4:14, del 17p or 1q gain/amplification. AEs were recorded using the CTCAE 5.0. AEs during DR combination therapy were compared with AEs during DARA monotherapy per patient-year.

Results: A total of 103 pts (62 males, 61%) were identified. The 1st line cohort included 48 pts. The median age was 73 (range 30-89) years. Their induction therapy included DR-dexamethasone (DRd) in 12 (25%) pts and DRd+bortezomib (V) in 36 (75%). Thirteen (27%) pts underwent ASCT. The median time from initiation of treatment to LEN d/c was 17.8 (range 1.5-54.2) months. Depth of response at the time of LEN d/c was sCR in 19, CR in 8, VGPR in 16 and PR in 5 pts. MRD was negative in 17/22 (77.3%) tested pts. After a median follow-up (F/U) of 22.9 (95% CI 15.5–30.3) months from LEN d/c, 12 (25%) pts experienced an event: 9 with PD, 2 changed therapy without PD, and 1 who received local radiotherapy. The median EFS from DR combination start and from LEN d/c were not reached (NR). The 3 years EFS rate from LEN d/c was 64.9±9.4%. Age (p=0.28), type of induction (with/without V; p=0.86), ASCT (p=0.74), duration of LEN administration (p=0.19) and depth of response (≥CR vs. VGPR or worst, p=0.57) had no impact on EFS. The advanced line cohort included 55 pts. The median age was 72 (range 37-85) years. Nearly all were in 2nd line (93%) and received DRd (90%). Median time from initiation of DR combination to LEN d/c was 24.3 (range 0.6-112.2) months. In a median F/U of 36.4 (95% CI 30.7-42.1) months from LEN d/c, 18 (32.7%) pts had an event (14 PD, 2 deaths and 2 regimen changes due to toxicity and insufficient response). Median F/U from DR combination start was 78.8 (95% CI 68.5-89.1) months. The median EFS from DR combination start and from LEN d/c was NR and 66.8 (95% CI 51.0-82.64) months, respectively. ISS (p=0.88), R-ISS (p=0.93), HR FISH (p=0.43) and duration of LEN administration (p=0.74) had no impact on EFS. Depth of response at the time of LEN d/c (≥CR vs. VGPR or worse) was the only factor associated with longer EFS: 73.9 (95% CI 48.8-99.1) months vs. 40.9 (95% CI 15.1-66.8) months, p-value=0.027. Older age tended to be associated with shorter EFS (HR 1.05 per year, 95% CI 0.99-1.1, p=0.07). In a multi variate analysis incorporating age and response at LEN d/c, age was not significantly associated with EFS (p=0.15) while depth of response approached significance (HR 0.3, 95% CI 0.08-1.08, p=0.07).
Safety: Reasons for LEN d/c in ≥3 pts included: GI symptoms (24%), cytopenias (22%), new/recurrence of SSM (14%), rash (12%), concurrent/suspected new MDS (including CCUS) and fatigue/malaise (7% each), peripheral neuropathy (5%), thrombotic/ischemic event (4%), infections and renal failure (3% each). A total of 583 treatment emergent (TEAEs) were recorded: 431 during DR combination and 152 during DARA monotherapy, yielding an event rate of 2.10 per patient-year during DR combination vs. 0.68 per patient-year during DARA monotherapy (p<0.001). Grade ≥3 TEAEs rate was 0.56 per patient-year on DR combination vs. 0.19 during DARA monotherapy (p<0.001). In a sensitivity analysis excluding TEAEs within 90 days of DR initiation, TEAEs rate remained significantly higher during DR therapy (1.62 vs. 0.68 per patient-year, p<0.001).

Conclusions: LEN d/c with continued DARA monotherapy may be feasible in selected pts and was associated with improved tolerability. Randomized trials are warranted to further evaluate the impact of this approach on efficacy and safety.

Tamir Shragai, MD: GSK - Honoraria; Takeda - Honoraria; Johnson & Johnson - Honoraria; Johnson & Johnson - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)